Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

inical trial activities, the timing of completing certain operational initiatives, our ability to effect reductions in certain aspects of our budgets in an efficient and timely manner, and changes in interest rates. These and other uncertainties may adversely affect our liquidity and capital resources to a significant extent and may force us to further reduce our expenditures on research and development or on our various new product and sales and marketing initiatives in order for us to continue to service our debt obligations. Such further reductions in our budgeted expenditures may have an adverse effect on our new product development and sales growth initiatives and reduce our ability to achieve the revenue growth targets, product launch or new product development timelines in our current operating plan. There can also be no assurance that such reductions in expenditures will be adequate to provide enough cash flow to continue to service our current level of debt obligations.

In particular, should our royalties received from BSC decline more significantly than we expect in future periods as a result of new competitive entrants into the U.S. drug-eluting stent market, our liquidity may be adversely affected, and we may be forced to explore alternative funding sources through debt, equity or other public or private securities offerings, or to pursue certain reorganization, restructuring or other strategic alternatives. There can be no assurance that if we pursue such financing activities that alternative sources of funding would be available to us on attractive terms, if at all. In addition, we may not be able to complete any restructuring, reorganization or strategic activities on terms that would be favorable for us or our shareholders. Capital markets conditions have deteriorated significantly during 2008 and 2009, including a significant and material decline in the level of corporate lending activity, combined with a significant increase in the cost of
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... January 14, 2014 Carahsoft and CDS ... January 23, 2014 at 2pm EST (11am PST), “Natural ... topic focuses on how technology can turn raw, heterogeneous ... for government agencies. The online webinar will last approximately ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... ... information company that develops and supplies irrigation management solutions. The company was approved for ... irrigation management control where “the plant is the sensor™.” , ... (Vocus) April 30, 2010 -- ...
... BEACH, California , and AMSTERDAM , April ... Meeting of the American Society of Breast,Surgeons, Agendia, a ... Research and Treatment has published an important study,demonstrating the ... breast cancer recurrence according to the MammaPrint test. The,ASBS ...
... April 29  Scotland will showcase the ... the world,s leading pharma and biotech companies to its ... in Chicago .  Heading into the conference, ... the nation,s unique integrated industry approach will continue to ...
Cached Biology Technology:$250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund 2New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy 2New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy 3Scotland Announces New Life Science Leadership and Investments at BIO 2010 2Scotland Announces New Life Science Leadership and Investments at BIO 2010 3Scotland Announces New Life Science Leadership and Investments at BIO 2010 4
(Date:7/9/2014)... July 9, 2014Biofuels derived from the oils produced by ... fuels. To achieve this goal, optimization of cost effective ... pond systems, is needed. Sapphire Energy has developed an ... pond algae cultivation systems, described in Industrial Biotechnology ... publishers. The article is available on the Industrial ...
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
(Date:7/9/2014)... era of increasing concern about the prevalence of ... a promising new pathway to disabling disease: blocking ... The scientists showed how bacterial siderophore, a small ... to fan bacterial growth as well as ... this infection process. Their findings appear in a ...
Breaking Biology News(10 mins):Controlling contamination in open algae ponds for biofuels 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Bacteria hijack plentiful iron supply source to flourish 2
... American Societies for Experimental Biology (FASEB) announces the opening ... DNA in Mammalian Genomes. Mobile elements have been ... and altering functions within mammalian genomes, and continue to ... explosion of data from high throughput sources, as well ...
... prepared a patient to inhale a panic-inducing dose of carbon ... the mixture, she cried for help, overwhelmed by the sensation ... her 40s known as SM, has an extremely rare condition ... amygdala, an almond-shaped area in the brain long known for ...
... for Experimental Biology (FASEB) announces the opening of registration ... and Flagella. The 2013 Biology of Cilia ... conference where basic and translational research intersect to drive ... ciliopathies. The underlying theme of the 2013 conference is ...
Cached Biology News:Human brain is divided on fear and panic 2Human brain is divided on fear and panic 3
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
Request Info...
Request Info...
Request Info...
Biology Products: